Cite
MLA Citation
Naiyer A Rizvi et al.. “Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.” Lancet oncology, vol. 16, no. 3, n.d., pp. 257–265. http://access.bl.uk/ark:/81055/vdc_100026002943.0x00001b